CL2017003097A1 - Composiciones y métodos para el tratamiento de la enfermedad celiaca - Google Patents

Composiciones y métodos para el tratamiento de la enfermedad celiaca

Info

Publication number
CL2017003097A1
CL2017003097A1 CL2017003097A CL2017003097A CL2017003097A1 CL 2017003097 A1 CL2017003097 A1 CL 2017003097A1 CL 2017003097 A CL2017003097 A CL 2017003097A CL 2017003097 A CL2017003097 A CL 2017003097A CL 2017003097 A1 CL2017003097 A1 CL 2017003097A1
Authority
CL
Chile
Prior art keywords
methods
waste
compositions
treatment
seq
Prior art date
Application number
CL2017003097A
Other languages
English (en)
Inventor
Ingrid Swanson Pultz
Clancey Wolf
Justin Bloomfield Siegel
Christine Elaine Tinberg
Lance Stewart
David Baker
Original Assignee
Univ Washington
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Univ California filed Critical Univ Washington
Publication of CL2017003097A1 publication Critical patent/CL2017003097A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

<p>SE DESCRIBEN POLIPÉPTIDOS Y MÉTODOS PARA SU USO QUE TIENEN UNA SECUENCIA DE AMINOÁCIDOS IDÉNTICA AL MENOS EN UN 75% A LA SECUENCIA DE AMINOÁCIDOS DE LA SEQ ID NO: 1, EN DONDE (A) EL POLIPÉPTIDO DEGRADA UN PÉPTIDO PFQPQLPY (SEQ ID NO: 140) Y/O UN PÉPTIDO PFPQPQQPF (SEQ ID NO: 68) A PH 4; (B) EL RESIDUO 467 ES SER, EL RESIDUO 267 ES GLU, Y EL RESIDUO 271 ES ASP; Y (C) EL POLIPÉPTIDO COMPRENDE UN CAMBIO DE AMINOÁCIDO DE SEQ ID NO: 1 EN UNO O MÁS RESIDUOS SELECCIONADOS DEL GRUPO QUE CONSISTE EN 221, 262E, 268, 269, 270, 319A, 320, 354E/Q/R/Y, 358S/Q/T, 368F/Q, 399, 402, 406, 424, 449, 461, 463, 105, 171, 172, 173, 174, Y 456.</p>
CL2017003097A 2015-06-08 2017-12-04 Composiciones y métodos para el tratamiento de la enfermedad celiaca CL2017003097A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562172557P 2015-06-08 2015-06-08

Publications (1)

Publication Number Publication Date
CL2017003097A1 true CL2017003097A1 (es) 2018-06-29

Family

ID=56194586

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017003097A CL2017003097A1 (es) 2015-06-08 2017-12-04 Composiciones y métodos para el tratamiento de la enfermedad celiaca
CL2023000752A CL2023000752A1 (es) 2015-06-08 2023-03-16 Composiciones y métodos para tratar la enfermedad celiaca

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023000752A CL2023000752A1 (es) 2015-06-08 2023-03-16 Composiciones y métodos para tratar la enfermedad celiaca

Country Status (26)

Country Link
US (4) US10793846B2 (es)
EP (1) EP3302518A1 (es)
JP (3) JP7325030B2 (es)
KR (2) KR20240152328A (es)
CN (1) CN107873053A (es)
AU (2) AU2016276436C1 (es)
BR (1) BR112017026142A2 (es)
CA (1) CA2988651A1 (es)
CL (2) CL2017003097A1 (es)
CO (1) CO2017013720A2 (es)
CR (1) CR20170567A (es)
DO (1) DOP2017000286A (es)
EA (1) EA037603B1 (es)
EC (1) ECSP17080844A (es)
HK (1) HK1245129A1 (es)
IL (3) IL317483A (es)
MX (2) MX392140B (es)
MY (1) MY189160A (es)
NZ (1) NZ737500A (es)
PE (2) PE20180509A1 (es)
PH (1) PH12017502213A1 (es)
SA (1) SA517390479B1 (es)
SG (1) SG10201911867YA (es)
TN (1) TN2017000520A1 (es)
WO (1) WO2016200880A1 (es)
ZA (1) ZA202302340B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882502A1 (en) 2011-08-10 2013-02-14 University Of Washington Through Its Center For Commercialization Compositions and methods for treating celiac sprue disease
US10266815B2 (en) 2013-08-14 2019-04-23 University Of Washington Through Its Center For Commercialization Compositions and methods for treating celiac sprue disease
NZ737500A (en) * 2015-06-08 2025-02-28 Univ Washington Compositions and methods for treating celiac sprue disease
EP3468597A1 (en) 2016-06-12 2019-04-17 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease
AU2017380106B2 (en) * 2016-12-22 2024-05-09 Ew Nutrition Gmbh Stable protease variants
MX2023004807A (es) 2020-10-30 2023-05-10 Univ Washington Composiciones y metodos para el tratamiento de la celiaquia.
JP7268911B2 (ja) * 2021-09-16 2023-05-08 株式会社ユニバーサルエンターテインメント 遊技機
JP7268910B2 (ja) * 2021-09-16 2023-05-08 株式会社ユニバーサルエンターテインメント 遊技機
EP4709834A1 (en) * 2023-05-11 2026-03-18 Digestiva, Inc. Wine dehazing methods and compositions
WO2025068987A1 (en) 2023-09-28 2025-04-03 Takeda Pharmaceutical Company Limited A method of producing a kumamolisin-as polypeptide

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688229B1 (fr) 1992-03-09 1995-06-23 Ulice Soc Procede de synthese enzymatique d'esters alkyliques de peptides, produits ainsi obtenus et utilisation desdits produits.
JP2002078489A (ja) * 2000-09-04 2002-03-19 Daiwa Kasei Kk セリン残基が活性発現に関与する新規酸性プロテアーゼ
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
AU2003215272B2 (en) 2002-02-14 2008-04-03 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7320788B2 (en) 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US7202216B2 (en) 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7265093B2 (en) 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
AU2003234634A1 (en) 2002-05-14 2003-12-02 Felix Hausch Drug therapy for celiac sprue
US7776545B2 (en) 2002-11-20 2010-08-17 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for Celiac Sprue
US7462688B2 (en) 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7563864B2 (en) 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7628985B2 (en) 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
US7534426B2 (en) 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
EP1600141B1 (en) 2004-05-24 2013-04-17 3M Deutschland GmbH Collagenolytic active enzyme containing compositions for the treatment of dental caries
EP1726643A1 (en) 2005-05-27 2006-11-29 Direvo Biotech AG Method for the provision, identification and selection of proteases with altered sensitivity to activity-modulating substances
AU2009283157B2 (en) 2008-08-21 2015-02-26 Alvine Pharmaceuticals, Inc. Formulation for oral administration of proteins
HU0900199D0 (en) * 2009-04-01 2009-06-29 Debreceni Egyetem Diagnosis of gluten-induced autoimmune diseases
EP2531521B1 (en) * 2010-02-02 2017-09-06 Amano Enzyme USA., Ltd. Use of proteases for gluten intolerance
CA2882502A1 (en) * 2011-08-10 2013-02-14 University Of Washington Through Its Center For Commercialization Compositions and methods for treating celiac sprue disease
ES2595500T3 (es) 2011-12-06 2016-12-30 Fondazione Istituto Insubrico Di Ricerca Per La Vita Nuevas proteasas que pueden hidrolizar péptidos y proteínas de gluten a un pH ácido, procedentes del actinomiceto Actinoallomurus
US10266815B2 (en) * 2013-08-14 2019-04-23 University Of Washington Through Its Center For Commercialization Compositions and methods for treating celiac sprue disease
CN105683275B (zh) * 2013-08-30 2018-10-02 莫门蒂夫性能材料股份有限公司 具有氨基酸的可湿固化的组合物
NZ737500A (en) * 2015-06-08 2025-02-28 Univ Washington Compositions and methods for treating celiac sprue disease

Also Published As

Publication number Publication date
CR20170567A (es) 2018-06-14
MX2022005483A (es) 2022-06-02
WO2016200880A1 (en) 2016-12-15
EA201792362A8 (ru) 2018-12-28
CN107873053A (zh) 2018-04-03
AU2016276436C1 (en) 2024-09-12
AU2022241520A1 (en) 2022-10-27
CO2017013720A2 (es) 2018-04-10
MX2017015786A (es) 2018-12-11
BR112017026142A2 (pt) 2018-08-14
PE20260442A1 (es) 2026-02-19
HK1245129A1 (zh) 2018-08-24
MX392140B (es) 2025-03-21
DOP2017000286A (es) 2018-03-30
ECSP17080844A (es) 2018-03-31
JP7429907B2 (ja) 2024-02-09
EA201792362A1 (ru) 2018-05-31
IL288768A (en) 2022-02-01
ZA202302340B (en) 2024-10-30
US11485961B2 (en) 2022-11-01
US20180142226A1 (en) 2018-05-24
KR102702879B1 (ko) 2024-09-04
AU2016276436B2 (en) 2022-07-07
JP2018517409A (ja) 2018-07-05
EP3302518A1 (en) 2018-04-11
IL256103A (en) 2018-02-28
TN2017000520A1 (en) 2019-04-12
KR20240152328A (ko) 2024-10-21
US20230130764A1 (en) 2023-04-27
EA037603B1 (ru) 2021-04-20
SG10201911867YA (en) 2020-01-30
JP7325030B2 (ja) 2023-08-14
NZ737500A (en) 2025-02-28
CA2988651A1 (en) 2016-12-15
CL2023000752A1 (es) 2024-04-12
SA517390479B1 (ar) 2022-11-10
US10793846B2 (en) 2020-10-06
JP2024041995A (ja) 2024-03-27
PH12017502213A1 (en) 2018-06-11
IL256103B (en) 2022-01-01
AU2016276436A1 (en) 2017-12-07
JP2021151250A (ja) 2021-09-30
KR20180023903A (ko) 2018-03-07
MY189160A (en) 2022-01-29
US10988748B2 (en) 2021-04-27
IL317483A (en) 2025-02-01
US20200109387A1 (en) 2020-04-09
US20210171928A1 (en) 2021-06-10
PE20180509A1 (es) 2018-03-09

Similar Documents

Publication Publication Date Title
CL2017003097A1 (es) Composiciones y métodos para el tratamiento de la enfermedad celiaca
EA202091710A1 (ru) Антитела против cd73 и способы их применения
EA201792651A1 (ru) Аденовирусные полинуклеотиды и полипептиды
MX392683B (es) Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso.
MX2020004578A (es) Composiciones de casz y metodos de uso.
PE20170665A1 (es) Anticuerpos anti-tau humanizados
BR112018015754A2 (pt) anticorpos anti-tnf, composições, métodos e uso para o tratamento ou prevenção de diabetes tipo 1
BR112019011860A2 (pt) proteína de fusão insulina-fc, sequência de ácido nucleico recombinante que codifica a mesma, vetor, célula eucariótica modificada, kit e método para tratar ou prevenir o diabetes autoimune
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
CL2016001405A1 (es) A peptide mixture
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
PE20181956A1 (es) Polipeptidos que inhiben cd40l
BR112018013246A2 (pt) rótulo de peptídeo e proteína rotulada incluindo o mesmo
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
PY1542559A (es) Genes de chromobacterium subtsugae
BR112017000710A2 (pt) polipeptídeo isolado, polipeptídeo modificado de revestimento final isolado, composição de matéria, polipeptídeo de fusão isolado, composição farmacêutica, método de tratamento de uma doença inflamatória, uso do polipeptídeo isolado, polinucleotídeo isolado, estrutura de ácido nucleico, e método de determinação da potência de um lote do polipeptídeo isolado
BR112018075613A2 (pt) peptídeos para o tratamento de osteoartrite
PE20190967A1 (es) Aislados modificados de streptomyces fungicidicus y su uso
AR107012A1 (es) ANTICUERPO QUE SE UNE ESPECÍFICAMENTE A ErbB3 Y EL USO DEL MISMO
MX2017005644A (es) Variantes de antigeno trypanosoma cruzi jl7 recombinante y su uso para detectar la enfermedad de chagas.
EA201792648A1 (ru) Аденовирусные полинуклеотиды и полипептиды
AR108848A1 (es) Genes de mini-distrofina optimizados y cassettes de expresión y su uso
AR104967A1 (es) Polinucleótido aislado, vector recombinante, adenovirus recombinante y composición que lo comprenden y su uso para preparar un medicamento
BR112018001207A2 (pt) novo peptídeo e uso do mesmo
TH176997A (th) ไซคลิกเปบไทด์ที่ได้มาจาก CD44v6 สำหรับการบำบัดโรคมะเร็งและโรคที่เกี่ยวข้อง กับการสร้างหลอดเลือดใหม่